Inducing apoptosis in colorectal - ChemoMetec A/S€¦ · Translation of the research into clinical...
1
Customer Testimonial ChemoMetec A/S | Gydevang 43, DK-3450 Allerød, Denmark | Tel: +45 48131020 | Fax: +45 48131021 | mail: [email protected] | www.chemometec.com ©2020 ChemoMetec | “Following a presentaon by colleagues from ChemoMetec, we found the NC-3000™ provides a fast, reliable and user-friendly device to invesgate the mechanisms of apoptosis. The use of this equipment saves a lot of me and effort and enables us to generate large data files in a very short period of me. Running mulple assays requiring only a single equipment source is also very cost effecve, parcularly when fundings are limited.” Dr. Farideh Javid, Reader in Pharmacology Challenges User Commentary Learn more about the University of Huddersfield lab at: hps://pure.hud.ac.uk/en/persons/farideh-javid The NucleoCounter ® NC-3000™ is an advanced image cytometer utilizing fluorescence imaging and advanced analysis alogorithms to characterize cell properties: • Pre-defined assays include a unique 5-minute Cell Cycle Assay and a selection of Apoptosis Assays • Easy to operate – no warm-up or calibration • Excellent support by field application specialists • Export data to FCS Express, FlowJo, etc. • Open platform with 5 fluorescent channels • CFR 21 Part 11 ready ® Advanced Cytometric data with NucleoCounter® NC-3000™ The main challenge to Dr. Javid and her team lies in establishing the precise involvement and interacon between central and peripheral cannabinoids and other pepdergic systems relevant to therapeuc advances in gastrointesnal and gynecological disorders. In their work, Dr. Javid’s team uses assays for apoptosis and cell cycle analysis to determine the effect of potenal drugs under invesgaon. The accuracy of the readout determines which drug candidates to pursue in further invesgaons as potenal drugs to fight gastrointesnal and ovarian cancers. In their drug screening, accuracy of data, reliability of analycal instruments, assay and readout speeds, lile maintenance or calibraon me, and ease of use for instrumentaon and equipment are all key factors that support faster and beer drug screens. Translaon of the research into clinical applicaons for paent benefit is ever movang to Dr. Javid and her team. Inducing apoptosis in colorectal and ovarian cancers Dr. Farideh Javid, commenced her research at the University of Huddersfield in 2008 as a Senior Lecturer and is currently Reader in Pharmacology. Her primary interest is in idenfying novel compounds originated from natural products, plants or synthecs for combang diseases, in parcular cancer. Her academic pursuits focus on drug discovery inducing apoptosis in colorectal and ovarian cancers, among others. She has collaborated with major pharma companies such as GlaxoSmithKline and GW Pharmaceucals, holding several patents on the an-cancer effects of non-psychoacve cannabinoids.
Transcript of Inducing apoptosis in colorectal - ChemoMetec A/S€¦ · Translation of the research into clinical...
Customer Testimonial
ChemoMetec A/S | Gydevang 43, DK-3450 Allerød, Denmark | Tel: +45 48131020 | Fax: +45 48131021 | mail: [email protected] | www.chemometec.com©2020 ChemoMetec |
“Following a presentation by colleagues from ChemoMetec, we found the NC-3000™ provides a fast, reliable and user-friendly device to investigate the mechanisms of apoptosis. The use of this equipment saves a lot of time and effort and enables us to generate large data files in a very short period of time. Running multiple assays requiring only a single equipment source is also very cost effective, particularly when fundings are limited.”
Dr. Farideh Javid, Reader in Pharmacology
Challenges
User Commentary
Learn more about the University of Huddersfield lab at: https://pure.hud.ac.uk/en/persons/farideh-javid
The NucleoCounter® NC-3000™ is an advanced image cytometer utilizing fluorescence imaging and advanced analysis alogorithms to characterize cell properties:
• Pre-defined assays include a unique5-minute Cell Cycle Assay and a selection of Apoptosis Assays
• Easy to operate – no warm-up or calibration
• Excellent support by field application specialists
• Export data to FCS Express, FlowJo, etc.
• Open platform with 5 fluorescent channels
• CFR 21 Part 11 ready
®
Advanced Cytometric datawith NucleoCounter® NC-3000™
The main challenge to Dr. Javid and her team lies in establishing the precise involvement and interaction between central and peripheral cannabinoids and other peptidergic systems relevant to therapeutic advances in gastrointestinal and gynecological disorders.
In their work, Dr. Javid’s team uses assays for apoptosis and cell cycle analysis to determine the effect of potential drugs under investigation. The accuracy of the readout determines which drug candidates to pursue in
further investigations as potential drugs to fight gastrointestinal and ovarian cancers.
In their drug screening, accuracy of data, reliability of analytical instruments, assay and readout speeds, little maintenance or calibration time, and ease of use for instrumentation and equipment are all key factors that support faster and better drug screens. Translation of the research into clinical applications for patient benefit is ever motivating to Dr. Javid and her team.
Inducing apoptosis in colorectal and ovarian cancers
Dr. Farideh Javid, commenced her research at the University of Huddersfield in 2008 as a Senior Lecturer and is currently Reader in Pharmacology. Her primary interest is in identifying novel compounds originated from natural products, plants or synthetics for combating diseases, in particular cancer. Her academic pursuits focus on drug discovery inducing apoptosis in colorectal and ovarian cancers, among others. She has collaborated with major pharma companies such as GlaxoSmithKline and GW Pharmaceuticals, holding several patents on the anti-cancer effects of non-psychoactive cannabinoids.
